Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics (NASDAQ: MCRB) announced the publication of Phase 3 ECOSPOR IV trial results in JAMA Network Open, showing that 91.3% of subjects were free from recurrent C. difficile infections at 8 weeks. The trial involved 263 participants and also indicated a significant improvement in health-related quality of life compared to placebo. The safety profile was consistent with prior trials, showing no treatment-related withdrawals. A Biologics License Application for SER-109 has been submitted to the FDA, with a PDUFA action date set for April 26, 2023. These results further support the company's efforts in microbiome therapeutics.

Seres Therapeutics (NASDAQ: MCRB) has commenced enrollment for Cohort 2 of its Phase 1b study of SER-155, an oral microbiome therapeutic aimed at reducing gastrointestinal infections and graft versus host disease in patients undergoing allogeneic hematopoietic stem cell transplantation. Following a positive review from the Data and Safety Monitoring Board, the company plans to report initial safety and pharmacological data from Cohort 1 in the upcoming months. SER-155's development is based on promising results from the Phase 3 SER-109 program. The company estimates over 9,000 patients receive allo-HSCT annually in the U.S., with significant associated management costs.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced on February 1, 2023 that its Compensation and Talent Committee granted inducement equity awards totaling 48,750 shares to eleven new employees. This includes stock options for 32,500 shares at an exercise price of $5.49 and restricted stock units (RSUs) for 16,250 shares. The equity grants are part of the 2022 Employment Inducement Award Plan adopted in December 2022. The stock options vest incrementally, while RSUs vest annually and quarterly after the first year.

Seres Therapeutics (NASDAQ: MCRB) announced on January 11, 2023, that its Compensation and Talent Committee granted equity awards to five new employees. This consists of 9,000 stock options at an exercise price of $5.26 per share and 4,500 restricted stock units (RSUs). The awards are governed by the Seres 2022 Employment Inducement Award Plan, which was established in December 2022 to attract new talent. Stock options vest over time, starting with 25% after one year of employment. Seres continues to develop innovative microbiome therapeutics aimed at treating diseases through functional interaction with host cells and tissues.

Seres Therapeutics (MCRB) has appointed Dr. Claire M. Fraser to its Board of Directors to bolster its microbiome therapeutic development efforts. Dr. Fraser, a leading figure in microbial genomics, expressed enthusiasm for joining at a pivotal time as the company anticipates the potential approval of its product SER-109 for recurrent C. difficile infection. Following a successful Data Safety Monitoring Board meeting in December, Seres plans to initiate enrollment of Cohort 2 in the SER-155 study in early 2023, aiming to address significant unmet needs in infection protection for medically compromised patients.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST. An audio webcast will be available on the company's website, with a replay accessible one hour after the event for 21 days. Seres is pioneering microbiome therapeutics, with its SER-109 program showing positive pivotal clinical results for treating C. difficile infections and receiving Breakthrough Therapy and Orphan Drug designations. The company is also advancing SER-155 in a Phase 1b study to protect against infections in stem cell transplant patients.

Seres Therapeutics (Nasdaq: MCRB) is set to host an investor webcast on December 8, 2022, at 8:30 a.m. ET, focusing on the commercialization of SER-109, aimed at treating recurrent C. difficile infection (rCDI). Following FDA acceptance of the Biologics License Application for SER-109, with a PDUFA action date of April 26, 2023, the webcast will discuss clinical data that showed an 88% sustained response in patients, compared to 60% on placebo. Attendees will include management and key medical professionals outlining unmet needs and commercialization strategies.

Seres Therapeutics, Inc. (MCRB) reported third quarter 2022 results and announced that the FDA has accepted its Biologics License Application (BLA) for SER-109 for recurrent C. difficile infection (rCDI) for Priority Review, with a target action date of April 26, 2023. SER-109 demonstrated an 88% sustained clinical response rate against 60% for placebo in Phase 3 trials. The company reported a net loss of $60 million this quarter, down from a net income of $68 million last year, while R&D expenditures rose. As of September 30, 2022, cash reserves stood at approximately $233 million.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call and audio webcast on November 2, 2022, at 8:30 a.m. ET, to discuss its third quarter 2022 results and a business update. The company is known for its innovative microbiome therapeutics, notably the SER-109 program, which has received Breakthrough Therapy and Orphan Drug designations from the FDA. SER-109 aims to prevent recurrent C. difficile infections. Seres is also advancing SER-155 in a Phase 1b study for patients with allogeneic transplants and exploring other microbiome therapeutics.